openPR Logo
Press release

A Flu Drug Baloxavir Marboxil Can Reduce Spread Within Households

A Flu Drug Baloxavir Marboxil Can Reduce Spread Within

A single dose of the flu drug baloxavir marboxil can reduce the spread of the illness within households, new research concludes.

A study examining 752 household contacts of 545 patients with the flu found that flu infections were much less common in household members who received the drug than among those who received a placebo. Only 1.9% of uninfected household contacts who took a single dose of baloxavir marboxil came down with the flu, compared with 13.6% of those who received the placebo.

"This trial established that baloxavir, if taken within a day or so after exposure, is highly effective for preventing influenza illness in households, a high-risk setting for virus transmission," said researcher Frederick G. Hayden, MD, of the University of Virginia School of Medicine. "The findings indicate that baloxavir prophylaxis should prove effective for prevention in other circumstances."

A study found that baloxavir marboxil, sold under the brand name Xofluza, was effective in adults, children and those at high-risk, regardless of whether they had received the flu vaccine. The frequency of adverse events, such as headaches and nausea, was similar among those who received the drug (22.2%) and those who received placebos (20.5%).

Hayden, a professor emeritus in UVA's Division of Infectious Diseases and International Health, was also part of a research team that published a month ago in Lancet Infectious Diseases that baloxavir treatment shortened the duration of influenza and reduced complications in adults and adolescents at high risk of complications. A single dose of the drug was as effective as a five-day course of oseltamivir (Tamiflu), the researchers concluded.

The FDA has approved baloxavir marboxil to treat flu within 2 days of symptom onset in people 12 years and older and those at high risk of developing complications. Its approval in 2018 marked the first novel flu drug in 20 years. The FDA is reviewing baloxavir applications for both treatment in children aged 1-11 years and for prophylaxis.

Huateng Pharma, a professional manufacturer of pharmaceutical API and intermediates, provides Baloxavir Marboxil intermediates such as CAS NO.2136287-68-6, CAS NO.1985607-70-2, CAS NO.2136287-66-4 and CAS NO.1985607-83-7 with capacities varying from gram to kilograms.

Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, P.R. China

Hunan Huateng Pharmaceutical Co. Ltd.
Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, P.R. China
Zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release A Flu Drug Baloxavir Marboxil Can Reduce Spread Within Households here

News-ID: 2094570 • Views: 419

More Releases from Hunan Huateng Pharmaceutical Co. Ltd.

Huateng Pharma Develops Systemic Antiparasitic Agent Fluralaner
Fluralaner is a systemic insecticide and acaricide that can be administered orally or topically. Bravecto is the trade name. The U.S. Food and Drug Administration (FDA) approved it for flea treatment in dogs under the trade name Bravecto in May 2014 and for topical treatment in cats in November 2019. Fluralaner is a novel isooxazoline broad-spectrum insecticide that acts on γ-aminobutyric acid (GABA) receptors and has good activity against ticks, fleas,
Huateng Pharma Develops Intermediates of Carfilzomib For Multiple Myeloma
Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B cell lineage, characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment, causing fractures and bone marrow failure, and is the second most common blood system disease in the world Tumors cannot be cured by traditional chemotherapy regimens. Bortezomib is the
Huateng Pharma Develops Intermediates of Semaglutide For TD2
According to the latest IDF Diabetes map, the global prevalence of diabetes reached 10.5% in 2021, with 537 million adults living with diabetes. China has become a disaster zone for diabetes, with the largest number of adults with diabetes in the world. In the past 10 years (2011-2021), the number of people with diabetes in China increased from 90 million to 140 million, an increase of 56%. The total number
The Future of Treatment For Type 2 Diabetes
Although the treatment of type 2 diabetes (T2DM) has made impressive progress in the past few decades, researchers are constantly searching for new treatments. How to better control blood glucose and reduce diabetes-related complications has become a hot topic in the field of T2DM research. Previously, The Lancet Diabetes Endocrinology published an in-depth review detailing novel therapeutic targets for T2DM, mechanisms of drug action, and corresponding hypoglycemic efficacy. It involves innovation

All 5 Releases

More Releases for Baloxavir

Global Influenza Drug Market Trends, Business Overview, Industry Growth and Fore …
The global influenza drug market is anticipated to grow at a significant CAGR 4% during the forecast period (2022-2028). The rising prevalence of influenza is creating a global demand for flu drugs, and the increase in the number of older people who are most affected by the disease is another factor driving the demand for influenza drugs. In addition, more focus on R&D to come up with new drugs and
Influenza Medication Market Overview by Recent Opportunities, Growth Size, Regio …
The global influenza medication market is expected to grow at a significant CAGR during the forecast period (2021-2027). Over the last few decades, the number of severe and life-threatening infectious diseases has increased across the globe. There are various kinds of influenza, which have exhibited a steady increase in occurrence globally. In October 2019, there were 9.7 million influenza cases in the US, according to the Centers for Disease
Influenza Virus B Infection Drug Market Comprehensive Insight by Growth Rate, In …
The global influenza virus B infection drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Influenza viruses cause nose, throat, and sometimes lungs infection. Its symptoms include fever, a cough, sore throat, and body aches. Additionally, type B influenza can cause more severe symptoms than a common cold however, in some cases, there is no need for medical attention. The major factor accelerating the
Global Pediatric Drugs Market Emerging Trend, Top Companies, Industry Demand, Bu …
The global pediatric drug market is projected to exhibit considerable growth during the forecast period (2019-2025). The high prevalence of the pediatric disorder, the rapid increase in the R&D activities related to the drug development process for the treatment of this disorder by the key players operating is a major factor anticipated to fuel the pediatric drug market during the forecast period. Novartis International AG, Genetech, Inc., Medimmune LLC, Johnson
Influenza Treatment Market Size Like to Extend $1.2 Billion by 2026
Influenza drugs are defined as the medicines which are employed for the treatment of patients suffering from influenza. Influenza is a viral infection caused by influenza viruses such as type A, type and type B. Furthermore, the virus is more serious in some group of people such as pregnant women, older people, young children, and people suffering from chronic diseases. Moreover, the infection manifests a wide range of clinical symptoms
Influenza Treatment Market Size to Reach $1.2 Billion by 2026
According to a new report published by Allied Market Research, titled, "Influenza Treatment Market by Product Type, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2018–2026," the global influenza treatment market size was valued at $862 million in 2018, and is expected to reach $1.2 billion by 2026, registering a CAGR of 4.5% from 2019 to 2026. know more: Influenza drugs are defined as the medicines which are employed for